Updated:
Shandong Weigao Group Medical Polymer Co.
Founded in 1988 in Weihai, Shandong, Shandong Weigao Group Medical Polymer Co.
Shandong Weigao Group Medical Polymer Co.
Founded in 1988 in Weihai, Shandong, Shandong Weigao Group Medical Polymer Co. began as a medical consumables manufacturer and has expanded into a state-owned enterprise spanning devices, pharmaceuticals, and medical digitalization. The group employs tens of thousands across subsidiaries including Weigao Orthopedics, which went public on Shanghai's STAR Market in 2021 (stock code 688161), and Weigao Blood Purification—a domestic leader in dialysis equipment and consumables. The company's strategy covers a broad asset-class mix: medical consumables (infusion sets, syringes), orthopedics (spine, trauma, joint, sports medicine), blood purification (dialyzers, machines, peritoneal dialysis), surgical robotics, interventional cardiology, IVD (immunoassay, biochemistry, coagulation, mass spectrometry), and digital health (HIS, EHR, smart nursing, DRG analytics). It operates through eight industrial groups: Weigao Medical Products, Weigao Orthopedics, Weigao Blood Purification, Weigao Pury (prefilled syringes), Weigao Commercial, Weigao Precision Surgery, Weigao Interventional, and Weigao Overseas. Products reach over 100 countries across Asia, Europe, the Americas, Africa, and Oceania. Confirmed portfolio subsidiaries include Weigao Orthopedics (688161.SH) and Weigao Blood Purification (per the firm's website, 2025). Total workforce figures across the group are not publicly consolidated; the medical products group alone reports nearly 10,000 employees, the commercial group 2,300+, and the blood purification unit roughly 3,600. The group maintains a single disclosed headquarters in Weihai, with additional R&D and manufacturing bases in multiple Chinese cities. In 2021, Weigao Orthopedics listed on the STAR Market, raising capital for orthopedic implant R&D. A recent operational event: April 2026 — Weigao partnered with Shanghai Ruijin Hospital to co-establish a smart medical device innovation and transformation space (per the firm, April 2026). A key structural differentiator is Weigao's integration of manufacturing, logistics, and digital services under one state-owned holding group. Its commercial arm operates a national warehousing network exceeding 460,000 square meters and supplies over 70% of China's top-tier hospitals through SPD (Supply-Processing-Distribution) and UDI systems, effectively blurring the line between a device manufacturer and a healthcare supply chain operator.
General information
Firm type
other
Year founded
1988
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Weihai
Corporate office
Weihai, Shandong, China
Sector focus
Frequently asked questions
Who controls investment decisions at Weigao Group?
Weigao Group is a state-owned enterprise (SOE) under the Shandong provincial government. The group's holding entity is Shandong Weigao Group Medical Polymer Co. No individual principals are publicly disclosed as controlling investment decisions; the corporate board and state-appointed management oversee capital allocation across the eight industrial groups.
Is Weigao structured as a single family office?
No. Weigao Group is a state-owned medical device and pharmaceutical enterprise, not a family office or asset manager. It operates as a holding company for industrial subsidiaries focused on manufacturing, R&D, and distribution of healthcare products. It does not manage external LP capital.
What is the wealth origin behind Weigao Group?
Weigao Group's founding capital originated as a collective township enterprise in Weihai, Shandong in 1988. Over time it transitioned to a state-owned enterprise. The specific initial wealth sources are not publicly attributed to any individual family.
What investment stages does Weigao target?
Weigao does not operate as an investment firm. Its capital deployment is primarily directed at internal R&D, manufacturing capacity expansion, and strategic acquisitions within the medical device and healthcare supply chain sectors. The group's public listing of Weigao Orthopedics in 2021 indicates a growth-phase exit strategy for a subsidiary.
How does Weigao source proprietary deal flow and technology?
Weigao's deal flow comes largely from internal R&D and partnerships with Chinese hospitals and research institutions, such as the April 2026 collaboration with Shanghai Ruijin Hospital. It also licenses foreign technology (e.g., prefilled syringe lines from Germany) and partners with international firms including Terumo and Nikkiso in blood purification.
Does Weigao participate in fund commitments?
Weigao is not an LP in external funds and does not publicly disclose fund commitments. Its capital is allocated to operating subsidiaries, factory construction, and technology licensing deals.
What sectors does Weigao explicitly avoid?
Weigao does not publicly disclose any sector avoidance. However, its disclosed product portfolio focuses exclusively on healthcare—medical devices, pharmaceuticals, and hospital digitalization—with no presence in finance, real estate, or consumer goods.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: